The decrease of HBsAg during nucleos(t)ide analogues (NUC) therapy in Bulgarian patients

References

• Lavanchy D. Hepatitis B virus epidemiology, disease burden, treatment and current emerging prevention and control measures. J Viral Hepatol. 2004;11:97–107.
   PubMed Web of Science ®Google Scholar
• McMahon BJ. The natural history of chronic hepatitis B virus infection. Hepatology. 2009;49(Suppl 5):S45–S55.
   PubMed Web of Science ®Google Scholar
• Kojuharova M, Kourtchatova A. Surveillance, epidemiology and prevention of hepatitis B in Bulgaria: results of the EUROHEP.net feasibility survey. In: EUROHEP.net book. Surveillance and prevention of vaccine preventable hepatitis. [Internet]. Universiteit Antwerpen, CEV/ESOC2004. [cited 22 Dec 2014]. Available from: www.EUROHEP.net 2001.
   Google Scholar
• Kevorkyan A, Teoharov P, Lernout T, Petrova N, Raycheva R, Ivanov I, van Damme P, Kojouharova M. Prevalence of HBV and HCV among outpatients in the plovdiv region of Bulgaria. J Med Virol. 2015;87(3)401–406.
   PubMed Web of Science ®Google Scholar
• Krastev Z, Tchernev K, Petrova D, Nikolovska D, Takov D, Marinova I, Chakurski I, Kotsev I, Antonov K, Katsarov K, Krastev N, Stoinov S, Tsvetanska A, Jelev D, Sabeva Z, Ivanova IL, Ivanova II. Todorova K, Genov J, Simonova M, Tzonev R, Mitova R, Balabanska R, Handjiev S. An open label, multicenter, national non-randomized study to evaluate efficacy and safety of Peginterferon alfa-2a (40 KD) in patients with HBeAg-negative chronic hepatitis B: preliminary results. Bulgarian Hepatogastroenterol. 2006;2:90–91.
   Google Scholar
• Jelev D. Chronic HBV infection: characteristics, natural course and options for treatment [ dissertation]. Medical University of Sofia (BG): DMSc; 2010.
   Google Scholar
• European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol. 2012;57:167–185.
   PubMed Web of Science ®Google Scholar
• Buster EH, Flink HJ, Cakaloglu Y, Simon K, Trojan J, Tabak F, So TM, Feinman SV, Mach T, Akarca US, Schutten M, Tielemans W, van Vuuren AJ, Hansen BE, Janssen HL. Sustained HBeAg and HBsAg loss after long-term follow-up of HBeAg-positive patients treated with peginterferon alpha-2b. Gastroenterology. 2008;135:459–467.
   PubMed Web of Science ®Google Scholar
• Moucari R, Korevaar A, Lada O, Martinot-Peignoux M, Boyer N, Mackiewicz V, Dauvergne A, Cardoso AC, Asselah T, Nicolas-Chanoine MH, Vidaud M, Valla D, Bedossa P, Marcellin P. High rates of HBsAg seroconversion in HBeAg-positive chronic hepatitis B patients responding to interferon: a long-term follow-up study. J Hepatol. 2009;50:1084–1092.
   PubMed Web of Science ®Google Scholar
• Yuen MF, Wong DK, Fung J, Ip P, But D, Hung I, Lau K, Yuen JC, Lai CL. HBsAg сeroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192–1199.
   PubMed Web of Science ®Google Scholar
• Wursthorn K, Jung M, Riva A, Goodman ZD, Lopez P, Bao W, Manns MP, Wedemeyer H, Naoumov NV. Kinetics of hepatitis B surface antigen decline during 3 years of telbivudine treatment in hepatitis B e antigen-positive patients. Hepatology. 2010;52:1611–1620.
   PubMed Web of Science ®Google Scholar
• Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084–1089.
   PubMed Web of Science ®Google Scholar
• Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow up. Hepatology. 2007;45:1187–1192.
   PubMed Web of Science ®Google Scholar
• Fattovich G, Giustina G, Sanchez-Tapias J, Quero C, Mas A, Olivotto PG, Solinas A, Almasio P, Hadziyannis S, Degos F, de Moura MC, Krogsgaard K, Pantalena M, Realdi G, Corrocher R, Schalm SW. Delayed clearance of serum HBsAg in compensated cirrhosis B: relation to interferon alpha therapy and disease prognosis: European Concerted Action on Viral Hepatitis (EUROHEP). Am J Gastroenterology. 1998;93:896–900.
   PubMed Web of Science ®Google Scholar
• Brunetto MR, Moriconi F, Bonino F, Lau GKK, Farci P, Yurdaydin C, Piratvisuth T, Luo K, Wang Y, Hadziyannis S, Wolf E, McCloud P, Batrla R, Marcellin P. Hepatitis B virus surface antigen levels: a guide to sustained response to peginterferon alfa-2a in HBeAg-negative chronic hepatitis B. Hepatology. 2009;49:1141–1145.
   PubMed Web of Science ®Google Scholar
• Tseng TC, Kao JH. Clinical utility of quantitative HBsAg in natural history and nucleos(t)ide analogue treatment of chronic hepatitis B: new trick of old dog. J Gastroenterology. 2013;48(1):13–21.
   PubMed Web of Science ®Google Scholar
• Chan HL, Thompson A, Martinot-Peignoux M, Piratvisuth T, Cornberg M, Brunetto MR, Tillmann HL, Kao JH, Jia JD, Wedemeyer H, Locarnini S, Janssen HL, Marcellin P. Hepatitis B surface antigen quantification: why and how to use it in 2011 – a core group report. J Hepatol. 2011;55(5):1121–1131.
   PubMed Web of Science ®Google Scholar
• Krastev Z, Jelev D, Ivanova A, Antonov K, Koseva O, Kotzev I, Ivanova I, Balabanska R. Maintenance Peginterferon alfa-2a treatment reduces HBsAg level in genotype D HBeAg-negative interferon responders (interim results). J Hepatol. 2011;54(Suppl. I):729.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Viganò M, Di Costanzo GG, Sagnelli E, Fasano M, Di Marco V, Boninsegna S, Farci P, Fargion S, Giuberti T, Iannacone C, Regep L, Massetto B, Facchetti F, Colombo M, PegBeLiver Study Group. Randomised study comparing 48 and 96 weeks peginterferon α-2a therapy in genotype D HBeAg-negative chronic hepatitis B. Gut. 2013;62(2):290–298.
   PubMed Web of Science ®Google Scholar
• Liaw YF, Jia JD, Chan HL, Han KH, Tanwandee T, Chuang WL, Tan DM, Chen XY, Gane E, Piratvisuth T, Chen L, Xie Q, Sung JJ, Wat C, Bernaards C, Cui Y, Marcellin P. Shorter durations and lower doses of peginterferon alfa-2a are associated with inferior hepatitis B e antigen seroconversion rates in hepatitis B virus genotypes B or C. Hepatology. 2011;54:1591–1599.
   PubMed Web of Science ®Google Scholar
• Piratvisuth T, Marcellin P, Popescu M, Kapprell HP, Rothe V, Lu ZM. Hepatitis B surface antigen: association with sustained response to peginterferon alfa-2a in hepatitis B e antigen-positive patients. Hepatol Int. 2013;7(2):429–436.
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Cakaloglu Y, Ferenci P, Tabak F, Akdogan M, et al. Early on-treatment prediction of response to peginterferon alfa-2a for HBeAg-negative chronic hepatitis B using HBsAg and HBV DNA levels. Hepatology. 2010;52:454–461.
   PubMed Web of Science ®Google Scholar
• Rijckborst V, Hansen BE, Ferenci P, Brunetto MR, Tabak F, CakalogluLanza AG, Messina V, Iannacone C, Massetto B, Regep L, Colombo M, Janssen HL, Lampertico P. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol. 2012;56:1006–1011.
   PubMed Web of Science ®Google Scholar
• Ganem D, Prince AM. Hepatitis B virus infection - natural history and clinical consequences. N Engl J Med. 2004;350:1118–1129.
   PubMed Web of Science ®Google Scholar
• Su TH, Hsu CS, Chen CL, Liu CH, Huang YW, Tseng TC, Liu CJ, Chen PJ, Lai MY, Chen DS, Kao JH. Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther. 2010;15:1133–1139.
   PubMed Web of Science ®Google Scholar
• Heathcote EJ, Marcellin P, Buti M, Gane E, De Man RA, Krastev Z, Germanidis G, Lee SS, Flisiak R, Kaita K, Manns M, Kotzev I, Tchernev K, Buggisch P, Weilert F, Kurdas OO, Shiffman ML, Trinh H, Gurel S, Snow-Lampart A, Borroto-Esoda K, Mondou E, Anderson J, Sorbel J, Rousseau F. Three-year efficacy and safety of tenofovir disoproxil fumarate treatment for chronic hepatitis B. Gastroenterology. 2011;140:132–43.
   PubMed Web of Science ®Google Scholar
• Zoutendijk R, Hansen BE, van Vuuren AJ, Boucher CA, Janssen HL. Serum HBsAg decline during long-term potent nucleos(t)ide analogue therapy for chronic hepatitis B and prediction of HBsAg loss. J. Infect. Dis. 2011;204:415–418.
   PubMed Web of Science ®Google Scholar
• Marcellin P, Buti M, Krastev Z, de Man RA, Zeuzem S, Lou L, Gaggar A, Flaherty JF, Massetto B, Lin L, Dinh P, Subramanian GM, McHutchison JG, Flisiak R, Gurel S, Dusheiko GM, Heathcote EJ. Kinetics of hepatitis B surface antigen loss in patients with HBeAg-positive chronic hepatitis B treated with tenofovir disoproxil fumarate. J Hepatol. 2014;61:1228–1237.
   PubMed Web of Science ®Google Scholar
• Reijnders JG, Rijckborst V, Sonneveld MJ, Scherbeijn SM, Boucher CA, Hansen BE, Janssen HL. Kinetics of hepatitis B surface antigen differ between treatment with peginterferon and entecavir. J Hepatol. 2011;54:449–454.
   PubMed Web of Science ®Google Scholar
• Kim GA, Lim YS, An J, Lee D, Shim JH, Kim KM, Lee HC, Chung YH, Lee YS, Suh DJ. HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. Gut. 2014;63(8):1325–1332.
   PubMed Web of Science ®Google Scholar
• Gish RG, Chang TT, Lai CL, de Man R, Gadano A, Poordad F, Yang J, Brett-Smith H, Tamez R. Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naive HBeAg-positive patients with chronic hepatitis B. J Viral Hepat. 2010;17:16–22.
   PubMed Web of Science ®Google Scholar
• Fung J, Lai CL, Young J, Wong DK, Yuen J, Seto WK, Yuen MF. Quantitative hepatitis B surface antigen levels in patients with chronic hepatitis B after 2 years of entecavir treatment. Am J Gastroenterol. 2011;106:1766–1773
   PubMed Web of Science ®Google Scholar
• Jaroszewicz J, Ho H, Markova A, Deterdig K, Wursthorn K, Schulz S, Bock CT, Tillmann HL, Manns MP, Wedemeyer H, Cornberger M. Hepatitis surface antigen (HBsAg) decrease and serum interferon-inducible protein-10 levels as predictive markers for HBsAg loss during treatment with nucleoside/nucleotide analogues. Antivir Ther. 2011;16:915–924.
   PubMed Web of Science ®Google Scholar
• Nikolova N, Jelev D, Antonov K, Krastev Z. HBsAg level after consecutive add-on peginterferon-alfa 2a and inosine pranobex in long-term responder to lamivudine, Poster session presented at European Gastro Update (1st European Update congress in Gastroenterology); 2014 May 16–17; Vienna, Austria.
   Google Scholar
• Kittner JM, Sprinzl MF, Grambihler A, Weinmann A, Schattenberg JM, Galle PR, Schuchmann M. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol. 2012;54:93–95.
   PubMed Web of Science ®Google Scholar
• Ouzan D, Pénaranda G, Joly H, Khiri H, Pironti A, Halfon P. Add-on peg-interferon leads to loss of HBsAg in patients with HBeAg-negative chronic hepatitis and HBV DNA fully suppressed by long-term nucleotide analogs. J Clin Virol. 2013;58(4):713–717.
   PubMed Web of Science ®Google Scholar
• Lampertico P, Colombo M, Brunetto MR, Craxì A, Gaeta B, Rizzetto M, Palmieri G. Add-on Peginterferon Alfa-2a significantly reduces HBsAg levels in chronic hepatitis B, HBeAg-negative, genotype D patients fully suppressed on nucleot(s)ide analogues treatment: HERMES study interim analysis. Poster session presented at AASLD November, 2014, Boston, USA.
   Google Scholar
• Cornberg M, Höner Zu Siederdissen C. HBsAg seroclearance with NUCs: rare but important. Gut. 2014;63(8):1208–1209.
   PubMed Web of Science ®Google Scholar